Bavarian Nordic A/S Stock

Bavarian Nordic A/S P/S 2024

Bavarian Nordic A/S P/S

2.63

Ticker

BAVA.CO

ISIN

DK0015998017

WKN

917165

As of Jul 11, 2024, Bavarian Nordic A/S's P/S ratio stood at 2.63, a 28.29% change from the 2.05 P/S ratio recorded in the previous year.

The Bavarian Nordic A/S P/S history

Bavarian Nordic A/S Aktienanalyse

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S is a biopharmaceutical company based in Denmark, specializing in the development and production of vaccines. The company was established in 1994 as a spin-off from the University of Copenhagen and has been listed on the Copenhagen stock exchange since 1998. The company's history began with an innovation developed by Professor Peter Andersen at the University of Copenhagen - the Viruslike Particles (VLP) technology. This technology serves as the basis for the production of vaccines against severe infectious diseases such as influenza, RSV, or HPV. Bavarian Nordic utilizes this technology to generate effective immune responses without using live pathogens. The company's business model is focused on two areas: the commercial vaccine sector and the biodefense products sector. The commercial sector includes the development and production of vaccines for cancer (such as prostate cancer or breast cancer) as well as infectious diseases like RSV. The biodefense products sector concentrates on protection against biological attacks, with the company manufacturing vaccines against bioweapons such as anthrax or smallpox for governmental institutions. Bavarian Nordic is divided into various business divisions. One of these is the commercial vaccines department, which develops and produces vaccines for the commercial market, particularly for cancer indications. The company also has a biodefense products department, which safeguards governmental institutions and organizations against bioterrorist attacks and other threats posed by biological weapons. This department focuses on the development and production of vaccines against smallpox, anthrax, and Ebola virus. Bavarian Nordic offers a wide range of products. The commercial vaccine Prostvac against prostate cancer is the company's flagship product. Other vaccines that have been developed or are still in development include vaccines against breast cancer, influenza, RSV, and lung cancer. The biodefense products encompass vaccines against smallpox, anthrax, and Ebola virus, as well as preclinical development programs for additional biological attacks. The company has also signed cooperation agreements with other companies to accelerate the research and development of new products. These include collaborations with Bristol Myers Squibb and Janssen Pharmaceutica for the development of cancer vaccines, as well as with the British Ministry of Defence for the development of vaccines against anthrax. Overall, Bavarian Nordic A/S caters to a broad range of interests and business sectors. The company focuses on the development and production of vaccines for both commercial and governmental institutions, aiming to enhance protection against biological threats and infectious diseases. Thanks to its innovative VLP technology, the company is a key player in the field of vaccine development and offers a wide range of products. Bavarian Nordic A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Bavarian Nordic A/S's P/S Ratio

Bavarian Nordic A/S's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Bavarian Nordic A/S's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Bavarian Nordic A/S's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Bavarian Nordic A/S’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Bavarian Nordic A/S stock

What is the price-to-earnings ratio of Bavarian Nordic A/S?

The price-earnings ratio of Bavarian Nordic A/S is currently 2.63.

How has the price-earnings ratio of Bavarian Nordic A/S changed compared to last year?

The price-to-earnings ratio of Bavarian Nordic A/S has increased by 28.29% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Bavarian Nordic A/S high compared to other companies?

Yes, the price-to-earnings ratio of Bavarian Nordic A/S is high compared to other companies.

How does an increase in the price-earnings ratio of Bavarian Nordic A/S affect the company?

An increase in the price-earnings ratio of Bavarian Nordic A/S would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Bavarian Nordic A/S affect the company?

A decrease in the price-earnings ratio of Bavarian Nordic A/S would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Bavarian Nordic A/S?

Some factors that influence the price-earnings ratio of Bavarian Nordic A/S are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Bavarian Nordic A/S pay?

Over the past 12 months, Bavarian Nordic A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bavarian Nordic A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Bavarian Nordic A/S?

The current dividend yield of Bavarian Nordic A/S is .

When does Bavarian Nordic A/S pay dividends?

Bavarian Nordic A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bavarian Nordic A/S?

Bavarian Nordic A/S paid dividends every year for the past 0 years.

What is the dividend of Bavarian Nordic A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bavarian Nordic A/S located?

Bavarian Nordic A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bavarian Nordic A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bavarian Nordic A/S from 7/11/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.

When did Bavarian Nordic A/S pay the last dividend?

The last dividend was paid out on 7/11/2024.

What was the dividend of Bavarian Nordic A/S in the year 2023?

In the year 2023, Bavarian Nordic A/S distributed 0 DKK as dividends.

In which currency does Bavarian Nordic A/S pay out the dividend?

The dividends of Bavarian Nordic A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Bavarian Nordic A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Bavarian Nordic A/S

Our stock analysis for Bavarian Nordic A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bavarian Nordic A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.